Introducing the 2020 Trainee Research Spotlight Award Winners!

by | Mar 1, 2020 | Education, Research

Dear Applicants and Fellow CCIC Trainees and Faculty,

I am excited to share with you the results of our 2020 Trainee Research Spotlight Award. This year, we received 20 diverse applications from excellent research trainees across Canada. Following review by our adjudication committee the following trainees have been selected to provide platform presentations at the 7th Annual Cannabinoids in Clinical Practice Conference:

• Andrew Roebuck, PhD Candidate, University of Saskatchewan (Supervisor Dr. J. Howland)

Andrew Roebuck

Mr. Roebuck’s work investigates how the endocannabinoid system may be involved in the pathology and treatment of absence epilepsy (AE). Current treatments for AE are not effective in all patients, fail to address cognitive comorbidities, and have many undesirable side effects. Using a rodent model, we are assessing the effects of cannabis, phytocannabinoids, and endocannabinoid modulation on seizures and behaviour. These projects have identified disruptions in the endocannabinoid system that may contribute to seizure generation and have provided evidence that synthetic endocannabinoid modulators can reduce seizure incidence. Ongoing research in our lab is investigating the effects of smoked cannabis on these seizures. The overall goal of this research is to further understand the role of the endocannabinoid system in AE and to develop cannabinoid therapies that can reduce seizures and improve clinical outcomes.

Andrew grew up in Saskatoon where he completed undergraduate degrees in Anatomy and Cell Biology and Psychology at the University of Saskatchewan. Before beginning grad school, Andrew packed his possessions into an old camper van and drove to the Yukon for what was to be just a few weeks. Five or so years later he returned to Saskatchewan and began working in the behavioural neuroscience lab of Dr. John Howland on projects related to absence epilepsy, stress effects on learning and memory, and drug development for schizophrenia. In addition to research, Andrew enjoys teaching physiology and neuroscience, and spent several years teaching biology as part of the Aboriginal Student Achievement Program. For all these opportunities Andrew is thankful for the support of his wonderful peers, mentors, and collaborators locally and abroad.


• Shahnaza Hamidullah, MSc Candidate, University of Guelph (Supervisor Dr. J. Khokhar)

Shahnaza Hamidullah

Ms. Shahnaza Hamidullah’s research focuses on investigating the long-term effects of adolescent alcohol and cannabis co-use on behaviour and cognition using a rat model. Cannabis and alcohol are commonly used by adolescents with co-use of these drugs being highly prevalent. However, evidence on the effects of co-use on subsequent adult behaviour is lacking. With this research, she hopes to empower youth with the information they need to make choices with potentially long-term implications. 

Shahnaza was born and raised in Tashkent, Uzbekistan and moved to Canada when she was 13 years old. She received her BSc and is currently an MSc candidate in Biomedical Sciences at the University of Guelph, specializing in the Collaborative Neuroscience Program. Growing up in an underprivileged community, she witnessed the broad-ranging impacts of substance use, which prompted her to focus her graduate studies on investigating the neuropharmacology of drugs of abuse in the lab of Dr. Jibran Khokhar. Her future goal is to combine research and medical training to help bridge the gap between basic research and delivery of quality patient care to those struggling with substance use.



• Roger Hudson, PhD Candidate, Western University (Supervisor Dr. S. Laviolette)

Roger Hudson

Mr. Hudson’s research investigates the neurobiology underlying the complex interactions between two major phytocannabinoids – THC and CBD. On the one hand, use of high potency THC-dominant cannabis can accelerate the onset of schizophrenia in genetically predisposed individuals, and elicit a psychotic-like state resembling schizophrenia in healthy individuals. On the other hand, CBD demonstrates antipsychotic efficacy and under particular circumstances can mitigate the neuropsychiatric side effects of THC. Hudson aims to shed light on the basic neurobiology of schizophrenia by demonstrating how the endocannabinoid system in the brain influences the onset of psychotic and cognitive symptoms in otherwise normal functioning systems. He also believes it may have implications for policy development around marijuana and other drugs of abuse.

 Roger grew up in Mississauga and confesses that science and school were not at the top of his list of interests when growing up. He credits one of his high school teachers for fostering his interest in education and sought a university degree in social working. His interest in science did not blossom until learning the basic pharmacology of how drugs affect the brain. While at the University of Guelph, Roger began volunteering in a neurobiology lab that focused on the learning and memory mechanisms of addiction. In particular, it was how this evolving knowledge could be translated into treatments for mental health disorders that led him to his current position as an PhD candidate in neuroscience in Dr. Steven Laviolette’s Lab at Western University. His long-term career goals are focused on contributing new knowledge to the field of neurobiology and making an impact on the lives of those who can benefit from his work. Ardent about science communication, he suggests podcasts to be an ideal platform for breaking down barriers to sci-comm and engage scientists and the public, alike – recently founding the “First-Person Science Podcast”. He is also a recipient of the Vanier Canada Graduate Scholarship, and is seeking Post-doctoral research positions beginning September 2021.


• Danielle Smith, PhD Candidate, University at Buffalo (Supervisor Dr. R. Lorraine Collins)

Danielle Smith

Ms. Smith’s current research focuses on behavioral and policy aspects related to individual and co-occurring nicotine and cannabis use through inhaled modes of delivery. As cannabis policies continue to become more liberal throughout the world, a key question is whether these changes will facilitate or hinder the use of other substances, such as tobacco and alcohol. To date, Ms. Smith’s work has demonstrated the significant overlap that exists between cannabis and nicotine use, evidenced using data ranging from biological markers of exposure and harm, through population-level information. Ms. Smith has led or co-authored over 30 scientific papers related to tobacco control, biomarkers, and cannabis use. Her work has been published in Addictive Behaviors, JAMA Network Open, Lancet Respiratory Medicine, Psychopharmacology, Nicotine and Tobacco Research, Tobacco Control, and Thorax.

Danielle was born and raised in Buffalo, NY. Her current career path was fueled by her broader interest in understanding the way people behave with respect to the use of substances and progression to addiction. She holds a joint BA in Psychology and Sociology, and an MPH from the University at Buffalo School of Public Health and Health Professions. In addition, she works as a Senior Research Specialist at Roswell Park comprehensive Cancer Center in Buffalo, NY. She is currently a fourth-year PhD candidate majoring in Community Health and Health Behavior under the guidance of R. Lorraine Collins, PhD.


• Andrew McLennan, B.A. Psychology, University of Calgary (Supervisors Dr. M. Kerba and Dr. L. Carlson)

Andrew McLennan

Cannabis has become a popular topic of discussion in cancer care and a growing numbers of patients are using it to manage the associated symptoms of cancer and its treatments. Recent studies show that cannabis is effective for helping patients mitigate symptoms of pain, nausea, appetite loss, sleep disturbance, etc., while producing few adverse effects. Although these findings are compelling, there remain many uncertainties surrounding cannabis in cancer and health care professionals face the difficult task of providing evidence-based recommendations to their patients. Andrew’s current research aims to investigate the implications of cannabis and cannabinoid compounds in cancer care, including factors surrounding its use in different patient populations, its efficacy for the treatment of cancer-related symptoms, and the perceptions and opinions of patients and oncology health care providers. 

Andrew was born in Red Deer, AB and grew up in the rural areas of central Alberta. Alongside a natural interest in music and athletics, Andrew has always had a curious mind and a desire to learn. This led him to pursue a bachelor’s degree in psychology at the University of Calgary, where he completed his honours thesis focused on cannabis use in oncology under the supervision of Dr. Linda Carlson. Andrew plays an active role on numerous ongoing cannabis-based projects at the Tom Baker Cancer Centre (Calgary, AB) with collaborators, Dr. Marc Kerba and Reanne Booker, and works as a research assistant for Dr. Linda Carlson in the Department of Psychosocial Oncology. He intends to pursue graduate studies in Clinical Psychology, where he hopes he can further contribute to cannabis-based literature.


• Jeremy Watts, University of Toronto (Supervisors Dr. R. Mizrahi and Dr. R. Ross)

Jeremy Watts

Jeremy Watts’ current work focuses on neuroimaging of the endocannabinoid system in psychotic disorders and neuromolecular alterations related to cannabis use. Given the strong associations between cannabis and psychosis, Jeremy is using multi-model imaging – positron emission tomography (PET) and proton magnetic resonance (1H-MRS) imaging – to identify and characterize alterations in neurometabolites (e.g., glutamate, GABA) and endocannabinoid metabolism related to heavy cannabis use and psychotic disorders. This work is necessary in order to gain a better understanding of how disturbances in these brain systems relate to pathology in long-term cannabis users and patients with schizophrenia spectrum disorders.

Born and raised in the Toronto area, Jeremy exhibited a fascination with science from a young age. At Queen’s University in Kingston, he came under the mentorship of Dr. Richard Beninger, beginning a period of intensive study that ignited a wide-eyed enthusiasm for the endocannabinoid system. As an undergraduate NSERC project, he investigated the role of anandamide in dopamine-mediated incentive learning. Jeremy undertook doctoral training at the only centre in the world with the ability to image the anandamide-metabolizing enzyme, FAAH, in vivo in the human brain, the CAMH PET Centre at the University of Toronto, under the supervision of Dr. Romina Mizrahi and Dr. Ruth Ross. Rigorous training on PET and 1H-MRS methods, grantsmanship and clinical study design and conduct have given him experience that will be invaluable to future successes in this field. Working directly with patients has been a transformative experience that has been central to his development as a scientist. Jeremy has presented his work at academic meetings hosted by the National Institutes of Drug Abuse, the American College of Neuropsychopharmacology and the International Cannabinoid Research Society, and is grateful for the opportunity to present at the 2020 meeting of the Canadian Consortium for the Investigation of Cannabinoids.

We wish to thank all of the applicants for submitting abstracts and we hope they will continue to do so for future competitions. Thanks to the adjudication committee for their hard work on this award as well.

Our latest:

CCIC 2.0

Welcome to CCIC 2.0! A lot has changed in the last year on the cannabis landscape in Canada, and here at the CCIC we have also undergone some significant changes. At the conclusion of the 5th Annual CCIC Congress in April 2018, the long standing Executive Director of the CCIC, Dr. Mark Ware, announced that he was stepping down from his role and that I was coming in as new ED.

Introducing the 2019 CCIC Trainee Spotlight Award Winners!

This year the CCIC held its first Trainee Spotlight Award competition. Six winners were selected by a panel of reviewers from among a pool of over 30 applications to give platform presentations of their exciting new research at this year’s Cannabinoids in Clinical Practice meeting (Toronto, March 21 and 22). The selected awardees are also provided with $1,000 and waived registration fees to offset the cost of travel to the meeting.

You might also like:

Introducing the 2019 CCIC Trainee Spotlight Award Winners!

This year the CCIC held its first Trainee Spotlight Award competition. Six winners were selected by a panel of reviewers from among a pool of over 30 applications to give platform presentations of their exciting new research at this year’s Cannabinoids in Clinical Practice meeting (Toronto, March 21 and 22). The selected awardees are also provided with $1,000 and waived registration fees to offset the cost of travel to the meeting.

Pin It on Pinterest

Share This

WE USE COOKIES TO OFFER YOU THE BEST EXPERIENCE ON OUR WEBSITE. BY CLICKING THE ACCEPT BUTTON, YOU AGREE TO OUR USE OF COOKIES IN ACCORDANCE WITH OUR COOKIE POLICY.